Read the anns 06/12/23
This trial is not sponsored by IMU and not under IMU's control. The Uni London has chosen PD1-Vaxx over Keytruda. Could be because of costs or, as they said, the superior properties of PD1-Vaxx.
Again, market gives a damn, but the scientists approve it.
Investors follow the sp, scientists follow the science. Who will get it right in the end?
GLTA
Ann: Imugene PD1-Vaxx Update, page-174
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
-0.001(1.47%) |
Mkt cap ! $490.4M | |||
| Open | High | Low | Value | Volume |
| 6.8¢ | 6.9¢ | 6.7¢ | $1.031M | 15.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1428024 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 485975 | 5 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
-0.001 ( 1.75 %) |
||||
| Open | High | Low | Volume | ||
| 6.8¢ | 6.9¢ | 6.7¢ | 4516697 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| IMU (ASX) Chart |